Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Alpha-1 Antitrypsin Deficiency Disease Treatment Market

Alpha-1 Antitrypsin Deficiency Disease Treatment Market Trends

Report ID: GMI11707
Published Date: Oct 2024
Report Format: PDF

Download Free Sample

Alpha-1 Antitrypsin Deficiency Disease Treatment Market Trends

The expansion of the market is significantly driven by the increasing prevalence of AATD, a genetic disorder that can lead to serious conditions such as chronic obstructive pulmonary disease (COPD) and liver disease. AATD affects approximately 1 in 2,500 individuals globally. However, the condition remains underdiagnosed, though awareness among healthcare providers and the public is growing, leading to increased identification and diagnosis rates. This heightened awareness, coupled with improved diagnostic capabilities, is driving demand for effective treatments.

As more individuals are diagnosed, the need for therapeutic options, including augmentation therapy, gene therapy, and other innovative treatments, is expanding. Pharmaceutical companies are responding by investing in the development of new and more effective therapies to meet this growing demand, recognizing the significant market potential. Additionally, government initiatives and support for rare diseases like AATD are contributing to market growth. Regulatory incentives, such as orphan drug designations, provide opportunities for companies to innovate and bring new treatments to market.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market was valued at USD 2.6 billion in 2023 and is projected to grow at a 10.1% CAGR from 2024 to 2032. This growth is driven by the rising incidence of related respiratory and liver diseases, increased awareness and screening programs, advancements in diagnostic technologies, and the development of effective treatment options.

The adult segment dominated the market with USD 2.3 billion in 2023, driven by increased disease awareness and advancements in therapeutic options.

The North American market is expected to grow at a 9.8% CAGR, reaching USD 2.9 billion by 2032. This growth is driven by significant advancements in therapeutic interventions and a high prevalence of AATD, particularly among the growing geriatric population.

Key players include Arrowhead Pharmaceuticals, Inc., CHIESI Farmaceutici S.p.A., CSL Behring, Epicrispr Biotechnologies, Inc., GlaxoSmithKline plc, Grifols S.A., Intellia Therapeutics, Inc., and Kamada Pharmaceuticals.